Veradermics, Inc. (MANE)

96.66 +6.34 (+7.03%) USD  |  NYSE  |  Jun 09, 16:00
96.66 0.00 (0.00%) After-Hours: 20:00
More

Veradermics SG&A Expense (Quarterly) : 8.937M for March 31, 2026

SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for MANE.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
Organon & Co. 424.00M
Tarsus Pharmaceuticals, Inc. 136.43M
ANI Pharmaceuticals, Inc. 73.66M
Corcept Therapeutics, Inc. 145.36M
Assertio Holdings, Inc. 11.14M